摘要
目的探讨利奈唑胺联合环丝氨酸在耐药肺结核患者中的治疗效果,以及对血清白介素-6(IL-6)、γ干扰素((IFN-γ)水平的影响。方法选择2017年12月至2020年12月福建省龙岩市第二医院收治的82例耐药肺结核患者作为研究对象,按随机数字表法分为研究组和对照组,各41例。对照组予以环丝氨酸治疗,研究组给予环丝氨酸+利奈唑胺治疗,均持续用药6个月。比较两组患者临床疗效、临床症状恢复情况、血清IL-6、IFN-γ及不良反应。结果研究组治疗总有效率高于对照组,病灶吸收缩小、痰培养转阴及抗酸染色涂片转阴时间短于对照组,差异有统计学意义(P<0.05);治疗前,两组患者血清IL-6、IFN-γ水平比较,差异无统计学意义(P>0.05);治疗后,研究组血清IL-6、IFN-γ水平低于对照组,差异有统计学意义(P<0.05);两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论利奈唑胺联合环丝氨酸治疗耐药肺结核效果良好,能够改善患者临床症状,降低血清IL-6、IFN-γ水平,且安全可靠。
Objective To investigate the therapeutic effect of Linezolid combined with Cycloserine in drug-resistant pulmonary tuberculosis patients and the effect on serum interleukin-6(IL-6)andγinterferon(IFN-γ)levels.Methods A total of 82 patients with drug-resistant pulmonary tuberculosis admitted to Second Hospital of Longyan City,Fujian Province from December 2017 to December 2020 were selected and divided into study group and control group according to the random number table method,with 41 cases in each group.The control group was treated with Cycloserine,and the study group was treated with Cycloserine+Linezolid,both of which continued to be treated for 6 months.The clinical efficacy,recovery of clinical symptoms,IL-6,IFN-γand adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group,the absorption of lesions,sputum culture and acid-fast staining smears were shorter than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in serum IL-6 and IFN-γlevels between the two groups(P>0.05);after treatment,the serum IL-6 and IFN-γlevels in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Linezolid combined with Cycloserine is effective in the treatment of drug-resistant pulmonary tuberculosis.It can improve the clinical symptoms of patients,reduce serum IL-6 and IFN-γlevels,and is safe and reliable.
作者
赖金梅
罗兰裕
刘锦华
LAI Jinmei;LUO lanyu;LIU Jinhua(Department of Tuberculosis,the Second Hospital of Longyan City,Fujian Province,Longyan364000,China)
出处
《中国当代医药》
CAS
2022年第14期55-57,62,共4页
China Modern Medicine
